About: Predictive and Prognostic Significance of Sodium Levels in Patients with NSCLC Treated by Erlotinib

Facets (new session)
Description
Metadata
Settings
- owl:sameAs
- Inference Rule:

About: Predictive and Prognostic Significance of Sodium Levels in Patients with NSCLC Treated by Erlotinib Goto Sponge NotDistinct Permalink

An Entity of Type : http://linked.opendata.cz/ontology/domain/vavai/Vysledek, within Data Space : linked.opendata.cz associated with source document(s)

Attributes	Values
rdf:type	skos:Concept http://linked.opendata.cz/ontology/domain/vavai/Vysledek
Description	Background: Hyponatremia is well known phenomenon in cancer patients. The aim of our retrospective study was to assess the relationship of natremia levels to predict treatment with erlotinib and also to assess the prognosis of patients with hyponatremia. Patients and metods: We analyzed data of 544 patients with advanced-staged non-small cell lung cancer treated with erlotinib. Results: Hyponatremia was measured in 21.5 % patients before treatment with erlotinib. We found a significant increase in the effectiveness of treatment with erlotinib in patients with normal levels of sodium to hyponatremic patients. PFS and OS was also significantly higher in patients with normal natremia. Multivariate Cox model then demonstrated that natrmia were independent factors for PFS and OS. Conslusion: We reported hyponatremia as not only prognostic marker in NSCLC patients but also as predictive marker of erlotinib treatment efficacy as independent factor at our large retrospective study. The possible effect for practise use in clinical practice is bigger thanks the simple possibility of testing of hyponatremia and the low cost of this biomarker. Background: Hyponatremia is well known phenomenon in cancer patients. The aim of our retrospective study was to assess the relationship of natremia levels to predict treatment with erlotinib and also to assess the prognosis of patients with hyponatremia. Patients and metods: We analyzed data of 544 patients with advanced-staged non-small cell lung cancer treated with erlotinib. Results: Hyponatremia was measured in 21.5 % patients before treatment with erlotinib. We found a significant increase in the effectiveness of treatment with erlotinib in patients with normal levels of sodium to hyponatremic patients. PFS and OS was also significantly higher in patients with normal natremia. Multivariate Cox model then demonstrated that natrmia were independent factors for PFS and OS. Conslusion: We reported hyponatremia as not only prognostic marker in NSCLC patients but also as predictive marker of erlotinib treatment efficacy as independent factor at our large retrospective study. The possible effect for practise use in clinical practice is bigger thanks the simple possibility of testing of hyponatremia and the low cost of this biomarker. (en)
Title	Predictive and Prognostic Significance of Sodium Levels in Patients with NSCLC Treated by Erlotinib Predictive and Prognostic Significance of Sodium Levels in Patients with NSCLC Treated by Erlotinib (en)
skos:prefLabel	Predictive and Prognostic Significance of Sodium Levels in Patients with NSCLC Treated by Erlotinib Predictive and Prognostic Significance of Sodium Levels in Patients with NSCLC Treated by Erlotinib (en)
skos:notation	RIV/00216208:11140/14:10285770!RIV15-MSM-11140___
http://linked.open...avai/riv/aktivita	I
http://linked.open...avai/riv/aktivity	I
http://linked.open...iv/cisloPeriodika	12
http://linked.open...vai/riv/dodaniDat	2015
http://linked.open...aciTvurceVysledku	Svatoň, Martin Brůha, František Fiala, Ondřej Pešek, Miloš Mukenšnábl, Petr Racek, Jaroslav
http://linked.open.../riv/druhVysledku	J - Článek v odborném periodiku
http://linked.open...iv/duvernostUdaju	S - Úplné a pravdivé údaje nepodléhající ochraně podle zvláštních právních předpisů
http://linked.open...titaPredkladatele	Univerzita Karlova v Praze / Lékařská fakulta v Plzni
http://linked.open...dnocenehoVysledku	38772
http://linked.open...ai/riv/idVysledku	RIV/00216208:11140/14:10285770
http://linked.open...riv/jazykVysledku	eng - angličtina
http://linked.open.../riv/klicovaSlova	predictive marker; prognosis; OS; PFS; NSCLC; hyponatremia (en)
http://linked.open.../riv/klicoveSlovo	predictive marker PFS hyponatremia NSCLC prognosis OS
http://linked.open...odStatuVydavatele	GR - Řecká republika
http://linked.open...ontrolniKodProRIV	[07A5CE752D35]
http://linked.open...i/riv/nazevZdroje	Anticancer Research
http://linked.open...in/vavai/riv/obor	FC
http://linked.open...ichTvurcuVysledku	6 (xsd:int)
http://linked.open...cetTvurcuVysledku	8 (xsd:int)
http://linked.open...UplatneniVysledku	2014
http://linked.open...v/svazekPeriodika	34
http://linked.open...iv/tvurceVysledku	Brůha, František Fiala, Ondřej Minárik, Marek Pešek, Miloš Racek, Jaroslav Mukenšnabl, Petr Bortlíček, Zdeněk Svatoň, Martin
http://linked.open...ain/vavai/riv/wos	000346689700077
issn	0250-7005
number of pages	5 (xsd:int)
http://localhost/t...ganizacniJednotka	11140

Faceted Search & Find service v1.16.118 as of Jun 21 2024

Alternative Linked Data Documents: ODE Content Formats:

RDF

ODATA

Microdata

About

OpenLink Virtuoso version 07.20.3240 as of Jun 21 2024, on Linux (x86_64-pc-linux-gnu), Single-Server Edition (126 GB total memory, 58 GB memory in use)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2024 OpenLink Software